Benefits of Dapagliflozin in HFmrEF/HFpEF Not Modified by AF at Baseline
Researchers evaluated if atrial fibrillation affects dapagliflozin therapy in patients with heart failure with preserved ejection fraction.
Treatments
ACC Recommendations on the Role of Nonstatin Therapies for Lowering LDL-C
In 2021, an expert panel assembled to review gaps in care related to treatments meant to lower LDL-C in patients with atherosclerotic cardiovascular disease.
OAC in Patients With AF and COVID-19 Lowers Rates of Death, Thrombotic Events
Researchers assessed the relationship between oral anticoagulation for patients with COVID-19 and AF and incidence of in-hospital thrombotic events and death.
Bebtelovimab Appears Reliable for COVID-19 During Omicron Epoch
For high-risk patients with mild-to-moderate COVID-19 during the omicron epoch, bebtelovimab seems to be a reliable treatment option.
Enoxaparin’s Effect on VTE and Major Bleeding After Bariatric Procedure
Investigators sought to determine the safety and efficacy of varying doses of enoxaparin regimens in patients receiving a bariatric procedure.
Decreased Arrhythmia Burden in High-Risk CVD With Targeted Potassium Levels
Researchers sought to determine if increased plasma potassium concentration decreases risk for malignant arrhythmia in high-risk patients with CVD.
Dapagliflozin Linked to Consistent Reductions in CV and Kidney Outcomes in T2D
A study was conducted to determine the efficacy and safety of dapagliflozin when taken with CV medications in patients with type 2 diabetes and HF, kidney disease, or both.
Hyperglycemia, Large Ischemic Core Volumes Seen in Acute Ischemic Stroke
Researchers sought to assess the association between hyperglycemia and CTP derived parameters in patients who had undergone EVT for acute ischemic stroke.
SGLTi Therapy Decreases Long-Term CVD and End-Stage Kidney Disease Risk in Type 1 Diabetes
A study was conducted to determine if SGLT2 inhibitors decrease risk for end-stage kidney disease or cardiovascular disease in patients with type 1 diabetes.
Dronedarone Reduces CV Hospitalization, Death in Patients With AF With, Without T2D
Researchers sought to assess the safety and efficacy of dronedarone therapy for patients with atrial fibrillation and diabetes.
- Loading...
Loading...
Next post in Type 2 Diabetes
Loading... 
Loading...